A Multicenter Study on Effects of Nefazodone(Serzone TM) on Depression, Anxiety, Sleep, Sexual Functions, and Quality of Life in Patients with Depression.
- Author:
Sung Kil MIN
1
;
Byung Jo KANG
;
In Kwa JUNG
;
Maeng Je CHO
;
Jin Sang YOON
;
Dong Kee KIM
;
Min Hee KANG
;
Doh Kwan KIM
;
Myung Jung KIM
;
Suk Hyung KIM
;
Yong Ku KIM
;
Jung Ki KIM
;
Min Cheol PARK
;
Gae Won BANG
;
Bong Ki SOHN
;
Ji Yong SHIN
;
Kang Seob OH
;
Bo Hyun YOON
;
Kyung Kyu LEE
;
Sang Keun CHUNG
;
Young Ki JUNG
;
In Won JUNG
;
Hee Yeon JUNG
;
Young Moe JE
;
Ik Seung CHEE
;
Byung Moo CHOI
;
Sun Ho HAN
;
Oh Su HAN
Author Information
1. Department of Psychiatry, Yonsei University, College of Medicine, Seoul. skmin518@yumc.yonsei.ac.kr
- Publication Type:Multicenter Study ; Original Article
- Keywords:
Nefazodone;
Antidepressant effect;
Anxiety;
Sleep disturbance;
Sexual dysfunction
- MeSH:
Anti-Anxiety Agents;
Anxiety*;
Depression*;
Depressive Disorder, Major;
Diagnostic and Statistical Manual of Mental Disorders;
Drug-Related Side Effects and Adverse Reactions;
Dysthymic Disorder;
Humans;
Quality of Life*;
Surveys and Questionnaires
- From:Korean Journal of Psychopharmacology
2001;12(3):211-221
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVE: The aim of this study is to determine effects of nefazodone on depression, anxiety, sleep and sexual function in depressive patients. SUBJECTS AND METHODS: This is an open, non-comparative, multi-center study. Antidepressant and other clinical effects of nefazodone were evaluated in 230 patients of 26 centers, aged 14 years or more, who met DSM-IV criteria to major depressive disorder or dysthymic disorder and didn't have other psychiatric disorders and were physically healthy. The clinical efficacy was assessed at week 1, 2, 4 and 8 using Clinical Global Improvement (CGI), Hamilton Depression Scale (HAM-D), Beck Depression Inventory (BDI), State and Trait Anxiety Inventory-State Anxiety (STAI-SA). Other clinical effects were assessed with Weekly Sleep Questionnaire, Sexual Functioning Questionnaire and GHQ-QOL-12, a scale for quality of life. Adverse drug reactions were checked with a questionnaire. Post-treatment effects of drug were compared with pre-treatment baseline condition. RESULTS: The response rates by Clincal Grobal Improvement and HAM-D after 8 weeks treatment were 62.4% and 75.2% respectively. Comparing to baseline, nefazodone was proved to have significantly higher antidepressant and antianxiety effects in depressive patients and it improved also sleep, sexual functions and quality of life. Both patients and physicians satisfied with the effects of drug. Adverse drug reactions were a few and not serious, and most of them disappeared as treatment continued. CONCLUSION: These results suggest that not only nefazodone has antidepressant effects and antianxiety effects, but also it improves sleep disturbance, sexual dysfunction and the quality of life in depressive patients. Adverse drug reactions were a few and not serious.
